Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Biocon Ltd is up for a third straight session in a row. The stock is quoting at Rs 380.1, up 3.22% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.06% on the day, quoting at 24018.3. The Sensex is at 76839.15, down 0.23%. Biocon Ltd has risen around 11.78% in last one month.
Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has risen around 10.1% in last one month and is currently quoting at 23568.95, up 2.16% on the day. The volume in the stock stood at 43.36 lakh shares today, compared to the daily average of 34.91 lakh shares in last one month.
The benchmark May futures contract for the stock is quoting at Rs 381.8, up 3.04% on the day. Biocon Ltd is up 9.7% in last one year as compared to a 1.62% drop in NIFTY and a 12.19% drop in the Nifty Pharma index.
The PE of the stock is 307.42 based on TTM earnings ending December 25.
Biocon announced that Health Canada has granted a Notice of Compliance (NOC) for Bosaya™ (denosumab), a biosimilar to Prolia®, and Vezuo™ (denosumab), a biosimilar to Xgeva®, on 03 April 2026. Both biosimilars were approved in the most common presentations: BOSAYA, as a 60 mg/mL injection for subcutaneous use in a prefilled syringe; and VEVZUO, as a 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial.
Denosumab products play a key role in bone health by increasing bone mass and treating osteoporosis, as well as bone complications associated with cancer.
Shreehas Tambe, CEO & Managing Director, Biocon, said, “Health Canada's approval of BOSAYA and VEVZUO marks another important milestone for Biocon as we continue to expand access to high-quality biosimilars in key global markets. This approval reflects our strong scientific and regulatory capabilities and reinforces our commitment to patients living with osteoporosis and cancer-related bone conditions, while further strengthening our portfolio of affordable biologic therapies across immunology and oncology.”
The approval is based on a comprehensive package of analytical, nonclinical, and clinical data, demonstrating that BOSAYA and VEVZUO are highly similar to PROLIA and XGEVA, respectively, with no clinically meaningful differences in quality, safety, or efficacy.
Shreehas Tambe, CEO & managing director, Biocon, said: “Health Canada’s approval of BOSAYA and VEVZUO marks another important milestone for Biocon as we continue to expand access to high-quality biosimilars in key global markets.
This approval reflects our strong scientific and regulatory capabilities and reinforces our commitment to patients living with osteoporosis and cancer-related bone conditions, while further strengthening our portfolio of affordable biologic therapies across immunology and oncology.'
Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.
The company's consolidated net profit surged to Rs 143.80 crore in the quarter ended December 2025 as against Rs 25.10 crore during the previous quarter ended December 2024. Sales rose 9.28% to Rs 4,123 crore in Q3 FY26 as compared with Q3 FY25.
Biocon Ltd is up for a fifth straight session today. The stock is quoting at Rs 362.1, up 0.85% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.77% on the day, quoting at 24552.55. The Sensex is at 79171.6, up 0.83%. Biocon Ltd has slipped around 1.38% in last one month.
Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has slipped around 1.88% in last one month and is currently quoting at 22456.75, up 0.05% on the day. The volume in the stock stood at 15.64 lakh shares today, compared to the daily average of 40.6 lakh shares in last one month.
The benchmark April futures contract for the stock is quoting at Rs 361.85, up 0.88% on the day. Biocon Ltd is up 8.48% in last one year as compared to a 1.59% jump in NIFTY and a 4.81% jump in the Nifty Pharma index.
The PE of the stock is 298.75 based on TTM earnings ending December 25.
Biocon Ltd gained for a third straight session today. The stock is quoting at Rs 356.2, up 1.55% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.31% on the day, quoting at 24272.2. The Sensex is at 78203, up 0.27%. Biocon Ltd has slipped around 6.9% in last one month.
Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has slipped around 0.72% in last one month and is currently quoting at 22465, up 0.02% on the day. The volume in the stock stood at 12.62 lakh shares today, compared to the daily average of 45.1 lakh shares in last one month.
The benchmark April futures contract for the stock is quoting at Rs 356.35, up 1.58% on the day. Biocon Ltd is up 7.32% in last one year as compared to a 0.61% spurt in NIFTY and a 5.24% spurt in the Nifty Pharma index.
The PE of the stock is 292.13 based on TTM earnings ending December 25.
Biocon Pharma, a subsidiary of Biocon, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Dapagliflozin Tablets, 5 mg and 10 mg.
The approved product is indicated for the treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control, and reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.
This approval further strengthens Biocon's expanding diabetes portfolio, which spans oral solid dosage formulations, biosimilar insulin, and complex GLP-1 peptides, reinforcing the Company's integrated approach to addressing the evolving needs of people living with diabetes globally.
Dapagliflozin Tablets will be manufactured at Biocon's FDA-approved facilities, in compliance with global quality and regulatory standards.
The approved product is indicated for the treatment of adults with type-2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control, and reduce the risk of hospitalization for heart failure in adults with type-2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors.
Dapagliflozin Tablets will be manufactured at Biocon’s FDA-approved facilities, in compliance with global quality and regulatory standards.
'This approval further strengthens Biocon’s expanding diabetes portfolio, which spans oral solid dosage formulations, biosimilar insulin, and complex GLP-1 peptides, reinforcing the company’s integrated approach to addressing the evolving needs of people living with diabetes globally,” the Bengaluru-based company said in a statement.
Biocon announced the commercial launch of Bosaya™ (denosumab-kyqq) and Aukelso™ (denosumab kyqq) in the United States.
Bosaya™ (biosimilar to Prolia®) and Aukelso™ (biosimilar to Xgeva®) are now available by prescription nationwide through specialty pharmacies and healthcare providers.
Both products have been previously approved and granted interchangeable designation by the U.S. Food and Drug Administration in September 2025, allowing substitution at the pharmacy level in accordance with state laws.
Shreehas Tambe, CEO & Managing Director, Biocon, said, “The U.S. introduction of Bosaya™ and Aukelso™ marks a strategic expansion of our biosimilars portfolio, building on our established leadership in oncology and immunology. These therapies broaden access to high-quality, affordable treatment options for patients living with serious bone conditions. This milestone underscores Biocon's strength as a portfolio development engine and our focus on building the world's most scalable access platform—advancing life-changing medicines for patients and health systems across the United States and around the world.”
Biocon has received approval from the U.S. FDA, for its complex formulation Liraglutide Injection, 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pens (gSaxenda®).
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management, indicated as an adjunct to a reduced-calorie diet and increased physical activity.
GLP-1 receptor agonists have emerged as one of the fastest growing therapeutic classes globally, driven by the rising prevalence of obesity and metabolic disorders, strong clinical outcomes, and increasing physician adoption.